- PureTech Health Cash Runway Extended
Sep 2, 2025
PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in consolidated operating expenses to $50 million from $66.7 million year-over-year in the first six months of 2025, and a sharpened focus on three core spinout entities: Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics. Management disclosed the external Series B valuation for Seaport Therapeutics of $733 million, presented third-party forecast modeling for future Cobenfy (KarXT) royalty revenues, potentially totaling $300 million through 2033 based on consensus analyst projections; this figure is a non-IFRS (non-GAAP) measure, and detailed progress on clinical milestones and financing plans across the portfolio.
PureTech Health accelerates spinouts, operational streamlining deepens cash runway
Following the spinout of Seaport Therapeutics in April 2024 and ongoing structural changes, the majority of operating and research and development (R&D) spending in the first half of 2025 is directed toward Celea Therapeutics and Gallop Oncology, which remain 100% owned but are actively moving toward independent external funding. Actual consolidated cash, cash equivalents, and short-term investments fell from $367 million at fiscal year 2024 (ended Dec. 31, 2024) to just under $320 million at the end of the first half of 2025 (as reported under GAAP), driven primarily by R&D spending on these two entities.
"the majority of the R&D spend, obviously, is attributed to Celea and to Gallop. So as we've indicated, I think, obviously, priority at the moment is looking to get those 2 assets funded with external capital. As they formally spin out, that will remove the majority of that spend from our balance sheet and from the sort of PureTech level P&L. So from that perspective, we would expect that as we go forward to have a further reduction on our R&D overhead as we move into 2026."
-- Robert Lyne, Interim Chief Executive Officer
The transition of R&D and operating expenses off the parent balance sheet is expected to extend PureTech Health’s cash runway beyond its current guidance of well into 2028, depending on the timing of external funding for portfolio entities, reducing future dilution risk.
Seaport Therapeutics valuation and economics clarify PureTech Health portfolio upside
PureTech Health retains a 35.1% equity stake and tiered (3%-5%) royalties in Seaport Therapeutics as of Aug. 2025, which recently closed a $733 million post-money Series B led by top venture investors including ARCH, Third Rock, and T. Rowe Price, as confirmed by management on the second quarter 2025 earnings call. Seaport Therapeutics is advancing three novel neuropsychiatric drugs via the proprietary Glyph platform that facilitates oral delivery of challenging therapeutics, a technology initially developed within PureTech Health.
"We have often had many questions on Seaport about the post-money valuation of that business. We still own just over 35% of the equity in Seaport Therapeutics. We also have tiered royalties on the drug products within that company because they were developed within PureTech originally. In terms of the valuation of Seaport, we have a valuation in our accounts, which is available publicly, but we have been asked in the past about the Series B valuation. And so we thought it would be helpful today to confirm that there was a $733 million post- money valuation on Seaport at the Series B, so a fairly recent financing, which was led by absolutely top-tier validated venture capital investors."
-- Robert Lyne, Interim Chief Executive Officer
This data point unlocks greater transparency for investors to model future PureTech Health value realization, benchmarks institutional appetite for the platform, and evidences management’s ability to crystallize significant off-balance sheet portfolio assets.
Cobenfy royalty stream de-risked with third-party forecasts
Cobenfy (KarXT), originally developed at PureTech Health and now licensed and marketed byBristol Myers Squibb(NYSE:BMY) afterKaruna Therapeutics(NASDAQ:KRTX)'s $15 billion acquisition, is expected to generate approximately $300 million in milestone and royalty payments for PureTech Health through 2033, based on consensus external analyst sales forecasts. The 2% royalty applies to annual sales exceeding $2 billion, and upside is linked to additional regulatory indications, notably pending pivotal Alzheimer’s psychosis data.
"We've been listening to shareholders very carefully about their feedback on the Cobenfy economics. We have repeatedly been asked whether we can give some indications around potential value by reference to third-party analyst forecasts. We'll be talking about that today, and we've taken the opportunity to do some indicative modeling around what those economics could look like against consensus analyst forecasts, and it's coming out as a value of around $300 million over time,"
-- Robert Lyne, Interim Chief Executive Officer
Providing third-party forecast modeling for Cobenfy royalties offers investors a more objective basis for valuing PureTech Health’s future cash flows and highlights the potential for further upside if additional indications are approved.
Looking ahead
Management indicated that an end of Phase II U.S. Food and Drug Administration (FDA) meeting for Celea Therapeutics’ deupirfenidone is expected in late third quarter 2025 (calendar year), with Phase III initiation targeted for the first half of 2026 (calendar year), subject to regulatory feedback. Top-line efficacy results from Gallop Oncology’s LYT-200 Phase Ib acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) study are expected in the fourth quarter of 2025, with additional survival and efficacy updates expected in the first half of 2026. Seaport Therapeutics’ near-term milestones remain undisclosed but are well funded following the $325 million capital raise as of Aug. 2025. No concrete new product pipeline timelines were provided beyond these disclosed milestones, and current cash runway extends into 2028, with further extension expected upon external funding of Celea Therapeutics and Gallop Oncology as of the second quarter of 2025.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,049%* — a market-crushing outperformance compared to 185% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor.
See the stocks »
*Stock Advisor returns as of August 25, 2025
This article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.</p>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Incyte stock rises as William Blair reiterates market perform rating
Jun 26, 2025
Investing.com - Incyte (NASDAQ:INCY) shares rose approximately 5% on Thursday following the company’s announcement of a CEO change, as William Blair maintained its Market Perform rating on the stock. According to InvestingPro data, the company’s stock is currently trading near its Fair Value, with a market capitalization of $13.6 billion and strong financial health metrics.
The biopharmaceutical company appointed Bill Meury as CEO and president, effective immediately, replacing Hervé Hoppenot who has been in the role since 2014 and will retire. Hoppenot will remain as a board member and advisor to the CEO through year-end to assist with the transition. InvestingPro analysis shows management has been actively buying back shares, with the company maintaining a healthy balance sheet showing more cash than debt.
Lead Independent Director Julian Baker has been elected chairman of the board as part of the leadership changes. William Blair noted that investors welcomed the announcement, as reflected in the stock’s positive movement. The company’s financial position appears solid, with a current ratio of 2.04 indicating strong liquidity and an impressive revenue growth of 17% in the last twelve months.
Meury brings significant leadership experience in the biopharmaceutical industry, most recently serving as CEO of Anthos Therapeutics, which Novartis (SIX:NOVN) acquired for up to $3.1 billion in February 2025. He previously led Karuna Therapeutics (NASDAQ:KRTX), which Bristol Myers (NYSE:BMY) purchased for $14 billion in December 2023.
William Blair analysts indicated that key questions will center on Meury’s assessment of Incyte’s pipeline, particularly which programs have the most potential to drive growth beyond Jakafi’s loss of exclusivity and which might be de-emphasized to reduce research and development spending.
In other recent news, Incyte announced a significant leadership change with Bill Meury taking over as President and CEO, succeeding Hervé Hoppenot who is retiring after 11 years. This transition also includes Julian Baker being elected as Chairman of the Board. Meury’s previous experience includes leading Anthos Therapeutics and Karuna Therapeutics through major acquisitions. Citi has reiterated its buy rating on Incyte, maintaining an $88.00 price target following these executive changes. Additionally, Incyte is navigating regulatory hurdles as the FDA has extended the review period for its ruxolitinib cream, intended for pediatric atopic dermatitis, by three months. This extension allows for a review of additional data on the cream’s formulation. The Phase 3 TRuE-AD3 study supporting this application met its primary endpoint, demonstrating the treatment’s potential efficacy. The cream has shown a consistent safety profile with no significant adverse events reported.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
- 30 Biggest Biotechnology Companies in the World
Mar 17, 2024
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World.
In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United Therapeutics, among others stand out for their innovative approaches and groundbreaking contributions to the field. These behemoths in biotech represent the forefront of scientific advancement, pioneering new therapies, diagnostics, and solutions to address pressing global challenges. From developing life-saving drugs to revolutionizing agricultural practices, the biggest biotechnology companies in the world play a pivotal role in shaping the future of healthcare, agriculture, and beyond.
Global Biotechnology Market Trends and Projections
The global biotechnology market is experiencing significant growth, with a projected value of USD 5.01 trillion by 2032. This market has been expanding rapidly due to various factors such as favorable government initiatives, plummeting sequencing prices, and increased demand for synthetic biology. Health-related applications have dominated the market, accounting for a substantial share in 2022. The market is characterized by key players like Johnson & Johnson (NYSE:JNJ) Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer, and others.
Johnson & Johnson (NYSE:JNJ), a key player in healthcare, plans to split into two companies focused on pharmaceuticals, medical devices, and consumer products. Their groundbreaking single-dose COVID-19 vaccine underscores their commitment to innovation, despite challenges. The company's medtech growth strategy, including investments in robotics and strategic acquisitions, positions it as a leader in the sector. Johnson & Johnson (NYSE:JNJ)'s Q1 2024 financial report showed a 22% sales decline to $138.6 million, with a net income of $4 million. Despite the decrease, the gross margin increased to 38.1%, with no debt and active inventory reduction plans.
Story continues
The U.S. biotechnology market size was USD 246.18 billion in 2023 and is projected to reach around USD 763.82 billion by 2033 with a CAGR of 11.90%. North America dominated the global biotechnology market in 2023 due to strong R&D initiatives and high healthcare expenses in the region. The U.S. market has seen significant contributions from major players and increased R&D activities, driving its growth trajectory. AstraZeneca PLC (NASDAQ:AZN), Gilead Sciences, Inc., Novo Nordisk A/S, and Abbott Laboratories are prominent companies driving innovation in therapeutics development within the biotechnology sector.
AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company, led by CEO Pascal Soriot and CFO Aradhana Sarin, focuses on innovative medicines, notably Tagrisso, a leading lung cancer treatment with sales exceeding $5.44 billion in 2022. Their pipeline includes Orpathys and Lynparza, expected to bolster lung cancer treatment. Despite a decline in COVID-19 medicine revenue, Q1 2024 saw a 6% total revenue increase to $45,811 million, with core EPS up by 15% to $7.26. AstraZeneca PLC (NASDAQ:AZN) anticipate FY 2024 revenue and core EPS to increase by a low double-digit to low teens percentage. AstraZeneca emphasizes ethical practices, sustainability, and inclusivity, investing $400 million in reforestation and making management changes. They've also announced collaborations for a novel RNA-based pandemic influenza vaccine and acquired Pfizer's early-stage rare disease gene therapy portfolio.
Illumina's Leadership in Genomic Advancements and the Future of Precision Medicine
In the realm of healthcare, genomic research and precision medicine have emerged as transformative forces, ushering in a new era where treatments are tailored to individual genetic profiles. Illumina, a leading figure in this field, has played a pivotal role in driving forward genomic progress through its innovative technologies and strategic collaborations. At the helm of this endeavor is Rami Mehio, the head of software and informatics at Illumina, whose contributions have been instrumental in spearheading major genomic initiatives such as the UK Biobank's whole-genome sequencing project.
One of Illumina's standout contributions lies in its DRAGEN pipeline, a groundbreaking technology that has revolutionized genomic data analysis by significantly enhancing sensitivity and precision in detecting genetic variants. Moreover, Illumina's collaborations with esteemed programs like the UK Biobank have facilitated large-scale whole-genome sequencing efforts, crucial for identifying rare variants associated with various diseases. Through strategic partnerships with research cohorts such as the All of Us program, Illumina has further accelerated drug discovery by leveraging genetic evidence to identify new drug targets.
Financially, Illumina has demonstrated a significant commitment to advancing genomic research. The company has made substantial investments in developing cutting-edge technologies like the DRAGEN pipeline. Notably, its support for the Precision Medicine Initiative, underscored by a $215 million investment in 2016, underscores its dedication to driving forward personalized healthcare.
Looking ahead, the future holds promise for even more precise medical treatments, particularly within the realm of synthetic biology. This advancement stands to have profound implications for drug discovery and disease management. However, it's essential to acknowledge the substantial financial investment required in pharmaceutical research and development. With the average pre-tax cost of developing a new drug or biologic standing at approximately $1.39 billion, the industry faces significant financial challenges.
The burgeoning field of genetic engineering, particularly advancements in gene-editing technologies, is poised to revolutionize healthcare by introducing new therapeutic categories such as cell therapy and gene editing. The genomic medicines industry is projected to grow substantially, with estimates suggesting it could reach $50 billion by 2028. Genomic sequencing technology, which has already transformed the healthcare industry, is anticipated to become more accessible, with the price per genome expected to decrease to $100 by 2025.
Despite the promise of gene therapy in treating previously intractable diseases, concerns about affordability persist due to the high prices of existing therapies. Nonetheless, gene therapy is expected to have a significant financial impact on the healthcare industry, with annual spending on approved therapies projected to reach $25.3 billion in 2026. 30 Biggest Biotechnology Companies in the World
A close up photograph of a vial of a new biotechnological drug candidate in development.
Our Methodology
For our methodology, we have ranked the biggest biotechnology companies in the world based on their current market cap. For the accuracy of data, we relied on Finviz.
Here is the list of 30 biggest biotechnology companies in the world.
30. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Market Cap: $5.38 billion
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biotech company, gained FDA approval for Rezdiffra™ (resmethrin) for Noncirrhotic Nonalcoholic Steatohepatitis (NASH). Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)'s fiscal Q1 2024 financials show $68,605 in R&D expenses, and $17,845 in general and administrative expenses, resulting in a $86,450 loss from operations. Interest income was $3,551, and interest expense was $2,900.
29. Blueprint Medicines Corporation (NASDAQ:BPMC)
Market Cap: $5.54 billion
Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the top biotech companies that specializes in precision therapies targeting genetic drivers, particularly in cancer treatment. They translate scientific discoveries into a diverse pipeline of promising therapies and have successfully delivered approved medicines for various cancers. In 2022, Blueprint Medicines Corporation (NASDAQ:BPMC)'s revenue reached $204.0 million, driven by sales of AYVAKIT/AYVAKYT and collaboration revenues.
28. CRISPR Therapeutics AG (NASDAQ:CRSP)
Market Cap: $6.14 billion
CRISPR Therapeutics AG (NASDAQ: CRSP) is renowned for its innovative therapies across various disease areas. The company's focus on CRISPR technology has led to groundbreaking advancements in treating genetic disorders and diseases. In Q1 2024, CRISPR Therapeutics AG (NASDAQ: CRSP) reported collaboration and grant revenue totaling $201.2 million, with a net income of $69.583 million.
27. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Market Cap: $6.20 billion
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a top biotechnology company in Carlsbad, California, specializes in RNA-targeted therapeutics, providing groundbreaking treatments for genetic disorders like SMA, hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)'s innovative approach targets diseases at the genetic level, offering hope to patients with unmet medical needs. In fiscal year 2023, they reported a revenue of US$788.0 million, marking a notable 34% increase from the previous year.
26. Cytokinetics, Incorporated (NASDAQ:CYTK)
Market Cap: $6.71 billion
Cytokinetics, Incorporated (NASDAQ:CYTK) is a leading biopharmaceutical company focusing on muscle activators and inhibitors for debilitating diseases. Their key drug candidates include omecamtiv mecarbil, in Phase III trials for heart failure, and CK-136, a cardiac troponin activator. Cytokinetics, Incorporated (NASDAQ:CYTK)made significant contributions to healthcare by addressing muscle dysfunction-related conditions. In 2023, their revenue was $7.53 million, reflecting a notable decrease from the previous year.
25. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Market Cap: $6.84 billion
Viking Therapeutics, Inc. (NASDAQ:VKTX), headquartered in San Diego, California is specializing in therapies for metabolic and endocrine disorders. They've developed several key drug candidates like VK2809 for non-alcoholic steatohepatitis (NASH), VK5211 for hip fracture recovery, and VK0612 for type 2 diabetes. In 2023, Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a net loss of $24.6 million or $0.25 per share.
24. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Market Cap: $6.84 billion
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is another one of the top biopharmaceuticals companies focused on innovative treatments for serious medical conditions. They've made significant strides in research and development, resulting in potential life-changing therapies. In 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)'s preliminary total U.S. product revenues reached approximately $366 million.
23. Exelixis, Inc. (NASDAQ:EXEL)
Market Cap: $6.97 billion
Exelixis, Inc. (NASDAQ:EXEL) is a leading oncology biotech known for CABOMETYX and COMETRIQ for tough cancers. They innovate in renal cell carcinoma, thyroid cancer, and melanoma. Developing new meds like zanzalintinib and XB002. In Q3 2023, Exelixis, Inc. (NASDAQ:EXEL) had total revenues of $471.9M, and net product revenues of $426.5M.
22. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Market Cap: $7.54 billion
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the biggest biotechnology companies in the world known for innovative pharmaceuticals in areas like oncology, neuroscience, and rare diseases. Their focus on cutting-edge treatments has positively impacted patient outcomes. In the first nine months of 2023, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported revenue close to $3 billion. Earnings per share stood at $5.02, slightly below expectations.
21. Vaxcyte, Inc. (NASDAQ:PCVX)
Market Cap: $7.56 billion
Vaxcyte, Inc. (NASDAQ:PCVX), headquartered in San Carlos, California ISfocusing on high-fidelity vaccines for bacterial infectious diseases. Their flagship vaccine candidate, VAX-24, aims to prevent invasive pneumococcal disease with broad-spectrum coverage. They're also developing other vaccines like VAX-31 and VAX-A1 targeting various bacterial strains. In 2023, Vaxcyte, Inc. (NASDAQ:PCVX) reported total operating expenses of $468.041 million, with $332.341 million invested in research and development to advance vaccine development programs.
20. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
Market Cap: $7.69 billion
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) is one of the biggest biotechnology companies in the world, specializing in therapies for neuroscience diseases such as schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. They focus on understanding disease biology to develop innovative treatments. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)'s pipeline includes promising candidates like Emraclidine, Darigabat, Tavapadon, and CVL-871, with ongoing or planned clinical trials, including Phase III trials for Parkinson's and Phase II trials for schizophrenia.
19. Roivant Sciences Ltd. (NASDAQ:ROIV)
Market Cap: $8.17 billion
Roivant Sciences Ltd. (NASDAQ:ROIV) stands nineteenth among the top biotech companies known for innovative contributions to healthcare. They've developed novel treatments across various therapeutic areas, positively impacting patient outcomes. In Q4 2023, Roivant Sciences Ltd. (NASDAQ:ROIV) reported an operating profit of 15,395 million CHF, with a net income of 12,358 million CHF. Core Pharmaceuticals sales reached 44,612 million CHF, while Diagnostics sales amounted to 14,104 million CHF.
18. Ascendis Pharma A/S (NASDAQ:ASND)
Market Cap: $8.42 billion
Ascendis Pharma A/S (NASDAQ:ASND), headquartered in Denmark is focusing on pharmaceutical products for various medical conditions globally. They've made significant contributions in areas like growth hormone deficiency and endocrinology, improving patient outcomes and addressing unmet medical needs. In Q4 2023, Ascendis Pharma A/S (NASDAQ:ASND)'s total investments amounted to $13,948,467, including $651,930 in the Consumer Staples sector and $5,338 in the healthcare sector.
17. United Therapeutics Corporation (NASDAQ:UTHR)
Market Cap: $11.10 billion
United Therapeutics Corporation (NASDAQ:UTHR) stands seventeenth among the biggest biotechnology companies in the world, known for its innovative pharmaceutical products, particularly in pulmonary arterial hypertension and infectious diseases. Their prostacyclin analogs like Remodulin, Tyvaso, and Orenitram are instrumental in treating pulmonary arterial hypertension. United Therapeutics Corporation (NASDAQ:UTHR) also develop engineered lungs for transplantation, showcasing pioneering approaches to healthcare challenges. In Q4 2023, their total revenues reached $614.7 million, with a net income of $217.1 million, reflecting strong financial performance.
16. Bio-Techne Corporation (NASDAQ:TECH)
Market Cap: $11.40 billion
Bio-Techne Corporation (NASDAQ:TECH) is one of the largest biotechnology companies known for its innovative contributions to healthcare through cutting-edge products and services. Their focus on research and development has facilitated advancements in genomics, proteomics, and drug discovery. With a total revenue of $1.14 billion as of the most recent quarter ending December 31, 2023, and healthy profit and operating margins of 19.58% and 18.39% respectively, Bio-Techne Corporation (NASDAQ:TECH) demonstrates strong financial performance and operational efficiency.
15. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Market Cap: $11.55 billion
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is known for pioneering treatments for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD) and neuromuscular disorders. Their innovative therapies aim to improve patient's quality of life. With a strong focus on research and development, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has made substantial advancements in biotechnology, addressing unmet medical needs and positioning itself as a key player in the healthcare industry.
14. Legend Biotech Corporation (NASDAQ:LEGN)
Market Cap: $11.64 billion
Legend Biotech Corporation (NASDAQ:LEGN) is a notable player in the biotech industry, specializing in innovative cell therapies for oncology and other indications. With global operations, particularly in the US and China, Legend Biotech Corporation (NASDAQ:LEGN) has received FDA approval for its CAR-T therapy, a significant advancement in cancer treatment, especially for relapsed and refractory multiple myeloma patients. In Q4 2023, license revenue was $35.2 million, down from $50.0 million in 2022, while collaboration revenue reached $249.8 million.
13. Karuna Therapeutics, Inc. (NASDAQ:KRTX)
Market Cap: $12.60 billion
Karuna Therapeutics, Inc. (NASDAQ:KRTX) is one of the biggest biotechnology companies in the world, focusing on transformative medicines for psychiatric and neurological conditions. Their lead product candidate, KarXT, shows promise in treating acute psychosis in adults with schizophrenia and psychosis in Alzheimer's disease. They're also developing KAR-2618 for mood and anxiety disorders. In Q4 2023, Karuna Therapeutics, Inc. (NASDAQ:KRTX) reported a net loss of $113.8 million, reflecting investments in research and development.
12. Incyte Corporation (NASDAQ:INCY)
Market Cap: $13.11 billion
Incyte Corporation (NASDAQ:INCY) is another top biopharmaceutical company known for innovative treatments like Jakafi and Opzelura. Jakafi has been pivotal in treating hematologic conditions and improving patients' quality of life, while Opzelura shows promise in addressing dermatologic disorders. Incyte Corporation (NASDAQ:INCY) has demonstrated impressive revenue growth, with total revenues increasing from $2.99 billion in 2021 to $3.70 billion in 2023. Product revenues have also risen steadily, with Jakafi's net revenues reaching $2.6 billion in 2023, and Opzelura showing robust growth with net product revenues of $109 million in Q4'23 and $338 million for FY'23.
11. Royalty Pharma plc (NASDAQ:RPRX)
Market Cap: $13.44 billion
Royalty Pharma plc (NASDAQ:RPRX), founded in 1996, acquires biopharmaceutical royalties and funds innovation in the sector. They support treatments like Spinraza and olpasiran through strategic acquisitions and co-funding late-stage trials. Royalty Pharma plc (NASDAQ:RPRX)'s portfolio includes royalties on over 35 products and 14 development-stage candidates. Portfolio Receipts for 2024 are estimated at $2.6-2.7 billion, with a 5-9% growth. Interest payments for the year are around $160 million, with $79 million projected for Q1 2024.
10. BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
Market Cap: $15.82 billion
Established in 1997, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is based in San Rafael, CA, specializing in genetic disorder treatments like PKU, CLN2 disease, MPS, and achondroplasia. Their mRNA therapies offer life-sustaining proteins for rare disorders. Q1 2024 saw total revenues rise to $646.2 million, up 20% year-over-year. Anticipating double-digit revenue growth and non-GAAP operating margin expansion, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) aims for $2.7 billion in total revenues for 2024.
9. BeiGene, Ltd. (NASDAQ:BGNE)
Market Cap: $16.25 billion
BeiGene, Ltd. (NASDAQ:BGNE) is one of the largest biotech companies in the world, known for innovative oncology treatments. In Q4 2023, they reported $630.5M in product revenue with an 83.2% gross margin. Full-year revenue was $2.2B with an 82.7% gross margin. BeiGene, Ltd. (NASDAQ:BGNE)'s operating expenses were $912.4M (GAAP) in Q4 and $3.3B (GAAP) for the year.
8. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Market Cap: $18.80 billion
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is known for its innovative RNA interference (RNAi) therapeutics, targeting specific genes to address genetic diseases at their root cause. With a robust pipeline and multi-product commercial portfolio, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a key player in the industry. In 2023, company's net product revenues reached $1.24 billion, marking a significant 39% growth.
7. Genmab A/S (NASDAQ:GMAB)
Market Cap: $19.57 billion
Genmab A/S (NASDAQ:GMAB), a Danish biotech leader, has specialized in innovative cancer antibody therapies since 1999. They develop cutting-edge platforms like bispecific T-cell engagers. With 20+ partnerships, they expand globally. Genmab A/S (NASDAQ:GMAB) aims to transform patient lives by 2030. Q1 2024 revenue surged 35% to DKK 2,854 million, boosted by royalties from Janssen and Novartis collaborations, and reimbursement from BioNTech SE.
6. BioNTech SE (NASDAQ:BNTX)
Market Cap: $21.98 billion
BioNTech SE (NASDAQ:BNTX), founded in 2008 in Mainz, Germany, stands sixth among the biggest biotechnology companies in the world, known for its contributions to healthcare, notably in immunotherapy. Their mRNA technology was pivotal in developing the Pfizer-BioNTech COVID-19 vaccine, aiding the global fight against the pandemic. In Q3 2023, BioNTech SE (NASDAQ:BNTX)'s revenues reached €895.3 million, with commercial revenues at €893.7 million and research & development revenues at €1.6 million.
Click to see and continue reading the 5 Biggest Biotechnology Companies in the World.
Suggested Articles:
27 Largest Biotech Companies in the US 12 Most Profitable Biotech Stocks To Invest In 20 Highest Paying Countries for Biotechnology
Disclosure. None: The 30 Biggest Biotechnology Companies in the World is originally published on Insider Monkey.
- 15 Highest Paying Jobs with a Psychology Degree
Mar 5, 2024
In this article, we discuss the 15 Highest Paying Jobs with a Psychology Degree. If you want to read about some more Highest Paying Jobs with a Psychology Degree, go directly to 5 Highest Paying Jobs with a Psychology Degree.
In the dynamic landscape of mental health, the global market has been witnessing an extraordinary surge, reaching a substantial valuation of USD 375.21 billion in 2022 and demonstrating an impressive growth trajectory, the Mental Health Market reached a valuation of USD 412.3 billion in 2023. It is projected to escalate to USD 615.2 billion by 2032 with a CAGR of 4.5% during the forecast period from 2024 to 2032. This growth is propelled by a confluence of factors, including an enhanced understanding of mental health issues, evolving societal perspectives, and advancements in technology that have revolutionized the way mental health services are delivered. Within this expansive field, a diverse range of mental health specialists, including therapists, psychologists, psychiatrists, and counsellors, collaboratively contribute to addressing the diverse needs of individuals grappling with mental health challenges. The projection of reaching US$38.42 billion in revenue for the Mental Health market by 2024 underscores the continued growth and significance of the mental health sector globally. The revenue is projected to demonstrate an annual growth rate of 0.67% from 2024 to 2028, leading to a market volume of US$39.46 billion by 2028. The United States is expected to generate the highest revenue globally, with US$11,730.00 million in 2024. These figures reflect an increasing acknowledgment of the importance of mental health and a corresponding surge in demand for mental health services and solutions.
The market dynamics further reveal intriguing insights, with mood disorders holding a significant 40% market share in 2022, while the segment of anxiety disorders presents a lucrative opportunity, forecasted to surpass USD 38 billion from 2023 to 2030. The psychological intervention segment is anticipated to surpass the USD 300 billion mark by 2027, underscoring the increasing reliance on therapeutic strategies for mental health treatment.
Story continues
Geographically, North America has emerged as the stronghold of the global mental health market, commanding a dominating 39% share and generating USD 154.86 billion in revenue in 2022. This supremacy is attributed not only to a well-developed healthcare infrastructure but also to a concerted effort in raising awareness and dismantling societal stigma surrounding mental health.
North America's success is further bolstered by the proactive inclusion of mental health coverage in many health insurance plans, rendering mental health services more accessible and cost-effective for a broader segment of the population. The region's strides in fostering an inclusive and comprehensive mental health ecosystem have resulted in a higher prevalence of individuals seeking and utilizing mental health services. On the contrary, the Asia-Pacific (APAC) region emerges as the market's fastest-growing segment, showcasing a remarkable CAGR exceeding 5.24%. The growth in APAC is not only reflective of economic expansion but also indicative of an increasing acknowledgment of mental health importance across diverse cultural landscapes.
Despite the undeniable growth in the mental health market, it's crucial to acknowledge the complexity of mental health conditions, often necessitating extended treatment periods and posing challenges to market expansion. However, the recent surge in telehealth and digital mental health adoption represents a promising avenue to address these challenges, offering innovative solutions for delivering mental health services efficiently. Numerous healthcare and biotech companies have been actively involved in the mental health sector, introducing innovative solutions and technologies to drive advancements in this market. So before moving onto our list of 15 Highest Paying Jobs with a Psychology Degree, let us take a look at a few of these companies and the contributions that they are making, namely, Bristol Myers Squibb (NYSE:BMY), Acadia Healthcare (NASDAQ:ACHC), and Compass Pathways plc (NASDAQ:CMPS).
Bristol Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY), a leading biopharmaceutical firm, specializes in developing and delivering advanced medicines to combat serious diseases. In the twelve months ending December 31, 2023, Bristol-Myers Squibb Company recorded revenue of $45.01 billion, reflecting a slight decrease of -2.50% compared to the previous year.
The company made a significant move in December 2023 with the acquisition of Karuna Therapeutics(NASDAQ:KRTX) for $14.0 billion. This acquisition, at a 53% premium, marks Bristol-Myers' entry into the realm of psychiatric and neurological treatments. Karuna's focus on developing medicines for these conditions, particularly its KarXT NDA for schizophrenia in adults, aligns well with Bristol-Myers' strategy of expanding into neuroscience. With the FDA's acceptance of KarXT's NDA for review by September 2024, Bristol-Myers anticipates substantial revenue growth in the latter half of the 2020s and beyond, propelled by its accelerated presence in the neuroscience sector.
Acadia Healthcare (NASDAQ:ACHC)
Acadia Healthcare (NASDAQ:ACHC), founded in 2005 in Franklin, TN, is the largest provider of behavioral health services in the U.S., operating 253 facilities with approximately 11,100 beds across 39 states and Puerto Rico.
Its revenue reached $2.93 billion in the twelve months ending December 31, 2023, growing by 12.20% year-over-year. Income distribution as of September 30, 2023, indicates acute care as the primary source (51%), followed by specialty (21%), comprehensive treatment centers (17%), and residential treatment centers (11%). Acadia's strategic plan focuses on expanding its facility count, improving substance abuse disorder care, and leveraging technology for better patient care.
COMPASS Pathways plc (NASDAQ:CMPS)
COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company operating in the UK and US, focuses on developing COMP360, a psilocybin therapy. In December, Compass Pathways announced positive feedback from its phase 2 study of the investigational COMP360 psilocybin treatment among individuals with PTSD (post-traumatic stress disorder). Currently, the company is conducting phase 3 trials, with anticipated results slated for the summer. Further results are expected by mid-2025.
Compass Pathways, like many early-stage biotech firms, incurred significant expenses with no revenue, losing $98.5 million in the first nine months of 2023, up $20.3 million from the previous year. To bolster its finances, it conducted a private placement in August, raising $125 million, with warrants accompanying ADSs potentially bringing in an additional $160 million if exercised. These warrants, with an exercise price of $9.93, are currently profitable.
This comprehensive context sets the stage for an exploration of the 15 Highest Paying Jobs with a Psychology Degree in the evolving and thriving mental health sector. By delving into the trends, growth factors, and geographical dynamics shaping the mental health market, this article aims to provide valuable insights for individuals considering a career in psychology, offering a roadmap to lucrative opportunities within the ever-evolving landscape of mental health services. 15 Highest Paying Jobs with a Psychology Degree
Olena Yakobchuk/Shutterstock.com
Methodology
Crafting a comprehensive guide to the 15 Highest Paying Jobs with a Psychology Degree demanded an in-depth exploration into professions attainable post-psychology degree. For this we referred to multiple sources including, Nexford University, Career Profiles, OLLU, Very Well Mind, PSYD Programs, Research.com, and University of Bridgeport. After compiling an extensive list of high-paying jobs related to the field of Psychology, we narrowed them down on the basis of their average annual salaries provided by Indeed. This left us with a thorough list of 15 Highest Paying Jobs with a Psychology Degree. From clinical domains to corporate spheres, the versatility of a psychology degree manifests in a spectrum of rewarding careers, each distinguished by its impactful contributions and competitive compensation. This article is a compass for those seeking both personal fulfillment and financial success in their professional journey after obtaining a psychology degree.
By the way, Insider Monkey is an investing website that tracks the movements of corporate insiders and hedge funds. By using a similar consensus approach, we identify the best stock picks of more than 900 hedge funds investing in US stocks. The top 10 consensus stock picks of hedge funds outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). Whether you are a beginner investor or professional one looking for the best stocks to buy, you can benefit from the wisdom of hedge funds and corporate insiders.
15 Highest Paying Jobs with a Psychology Degree
15. Career Counsellor
Average AnnualSalary:$46,917
Career counsellors assist individuals in discovering the most fitting job for them by administering aptitude and achievement tests that assess their skills, interests, and abilities. Additionally, these professionals consider the individual's educational background and work experience as integral factors in the career guidance process.
14. Substance abuse counsellor
Average AnnualSalary: $54,351
Substance abuse counsellors play a crucial role in supporting individuals grappling with addiction. They lend a compassionate ear, aid in managing the challenges individuals face, and formulate personalized treatment plans to address their substance abuse issues.
13. School psychologist
Average AnnualSalary:$56,279
School psychologists focus on supporting children and young adults by actively listening to their concerns and issues, particularly in the realms of academics and social interactions. Drawing insights from these conversations, they assist students in developing coping strategies to navigate and overcome the challenges they encounter.
12. Guidance counsellors
Average AnnualSalary:$56,870
Guidance counsellors support students in developing both academic and social skills. By closely observing their performance in the classroom, these professionals assist students in identifying and achieving their goals.
11. Director of social services
Average AnnualSalary:$58,289
The role of a Director of Social Services involves overseeing a social services department and developing programs to support diverse individuals. Essentially, individuals in this position are social workers who have assumed managerial responsibilities. In addition to managing programs, they also conduct patient assessments and assist individuals in adapting to new circumstances and situations.
10. Special education teacher
Average AnnualSalary:$60,212
Special education teachers are responsible for instructing students who have diverse disabilities, encompassing mental, emotional, physical, or learning-related challenges. They design tailored lesson plans to address the specific needs of these students, ensuring a supportive and inclusive educational experience.
9. Family therapist
Average AnnualSalary:$66,909
Family therapists play a crucial role in addressing family and marital issues, working with individuals either in group or individual settings. By identifying and understanding the issues at hand, they offer guidance and mediation to help families navigate and resolve their challenges.
8. Licensed professional counsellor
Average AnnualSalary: $68,118
Licensed professional counsellors are professionals dedicated to aiding individuals dealing with mental health issues. They provide support for a range of concerns, including psychological and emotional challenges. Additionally, these counsellors may choose to specialize in particular areas within the field to offer targeted assistance to their clients.
7. Clinical supervisors
Average AnnualSalary:$77,331
Clinical supervisors play a crucial role in developing client treatment plans by assessing clinical records. They review casework, address employee concerns, and strive to foster a positive and constructive relationship between supervisors and employees. Additionally, they contribute to maintaining a healthy and effective work environment within the clinical setting.
6. Licensed clinical social worker
Average AnnualSalary:$82,696
Sixth on our list of 15 Highest Paying Jobs with a Psychology Degree is Licensed clinical social worker. Licensed clinical social workers play a pivotal role in creating treatment plans for their clients, drawing insights from their observations and the specific needs of the individuals they serve. Additionally, they diagnose various behavioural, emotional, and psychological disorders to formulate more effective and tailored treatment plans for the well-being of their clients.
Click to continue reading and find out about 5 Highest Paying Jobs with a Psychology Degree.
Suggested Articles:
25 Best Online Psychology Degree Programs Heading Into 2024 12 Healthcare Stocks Billionaires Like the Most 20 Countries with Free Health Care
Disclosure: None. 15 Highest Paying Jobs with a Psychology Degree is originally published on Insider Monkey.
- Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Feb 23, 2024
Karuna Therapeutics, Inc. KRTX reported a loss of $3.01 per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $2.64.
In the year-ago quarter, the company posted a loss of $2.22 per share. The loss increased from the year-ago quarter due to higher operating expenses.
In the fourth quarter of 2023, Karuna did not record any revenues. Sales missed the Zacks Consensus Estimate of $2.9 million. In the year-ago quarter, the company recorded $5.3 million in licensing revenues.
Quarter in Detail
In the reported quarter, research and development expenses were $82.2 million, up 24.5% from the year-ago quarter’s figure, due to increased costs related to lead pipeline candidate KarXT (xanomeline-trospium) plus higher employee-related expenses.
General and administrative expenses surged almost 95% year over year to $47.4 million, driven by pre-commercialization activities for KarXT and higher employee-related costs.
As of Dec 31, 2023, Karuna had cash, cash equivalents and marketable securities of $1.3 billion, similar to what it had as of Sep 30, 2023.
Shares of Karuna have rallied 61.5% in the past year against the industry’s decline of 8.5%. Zacks Investment Research
Image Source: Zacks Investment Research
Full-Year Results
In 2023, Karuna generated revenues of $0.6 million compared with $10.6 million generated in 2022.
In the same period, the company recorded a loss per share of $11.73 compared with $8.74 in 2022.
Recent Updates
Karuna is all set to be acquired by drug giant Bristol Myers BMY for a total equity value of $14 billion.
In December 2023, the companies entered into a definitive merger agreement wherein Bristol Myers agreed to acquire all outstanding shares of Karuna for $330 per share in cash.
The transaction, expected to be completed by first-half 2024, is subject to customary closing conditions and clearance from regulatory authorities. Karuna and BMY’s board of directors have already approved this transaction.
An acquisition by Bristol Myers, which has high reserves of cash flow, would enable the company to ramp up the development of its pipeline.
Story continues
Karuna’s KarXT is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety. The new drug application for KarXT for treating schizophrenia in adults is currently under review in the United States. The FDA has set a target action date of Sep 26, 2024.
If approved, KarXT will provide a new treatment option for patients and be the first novel pharmacological approach for schizophrenia treatment in several decades.
KarXT is being evaluated in the phase III ARISE study as adjunctive treatment in schizophrenia. Top-line data from this study is expected in 2025. Meanwhile, the phase III ADEPT-1 and ADEPT-2 studies are evaluating KarXT in psychosis in Alzheimer’s disease. Top-line data from this study is expected in 2026.
In November 2023, the company announced positive data from a phase Ib study evaluating the effect of KarXT on ambulatory blood pressure in adults with schizophrenia. Data from the study showed that treatment with KarXT was not associated with clinically meaningful increases in blood pressure in the given patient population.
Karuna plans to initiate a phase Ib study evaluating KAR-2618, a TRPC4/5 inhibitor, to treat major depressive disorder later in 2024.
Karuna Therapeutics, Inc. Price, Consensus and EPS Surprise Karuna Therapeutics, Inc. Price, Consensus and EPS Surprise
Karuna Therapeutics, Inc. price-consensus-eps-surprise-chart | Karuna Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Karuna currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the healthcare sector are Vanda Pharmaceuticals Inc. VNDA and Puma Biotechnology, Inc. PBYI, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, shares of VNDA have plunged 33.1%.
Vanda Pharmaceuticals’ earnings beat estimates in each of the trailing three quarters. VNDA delivered an average earnings surprise of 92.88%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved to 71 cents from 64 cents. In the past year, shares of PBYI have risen 49.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
Vanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report
Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
- Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Feb 23, 2024 · zacks.com
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
- Decoding Karuna Therapeutics Inc (KRTX): A Strategic SWOT Insight
Feb 23, 2024
Strengths: Innovative CNS-focused pipeline with lead candidate KarXT showing promise in clinical trials. Weaknesses: Clinical-stage status with significant ongoing R&D expenses and no product revenue. Opportunities: Potential market expansion through strategic collaborations and additional indications for KarXT. Threats: Intense competition in the neuropsychiatric drug market and regulatory hurdles.
Warning! GuruFocus has detected 5 Warning Signs with KRTX.
On February 22, 2024, Karuna Therapeutics Inc (NASDAQ:KRTX), a clinical-stage biopharmaceutical company, filed its annual report (10-K) with the SEC, offering a comprehensive view of its financial health and strategic positioning. With a focus on developing novel therapies for neuropsychiatric conditions, KRTX's lead product candidate, KarXT, is an oral modulator of muscarinic receptors with potential applications in schizophrenia and Alzheimer's disease psychosis. As of the end of the fiscal year 2023, the company reported a substantial market valuation of $5,872.6 million, with 38.15 million shares of common stock outstanding. Despite not generating product revenue, KRTX has maintained a robust R&D pipeline, with prepaid research and development expenses totaling $35.7 million. The company's financial strategy is supported by follow-on public offerings and an equity distribution agreement, enhancing its capital position for continued investment in its promising pipeline. Decoding Karuna Therapeutics Inc (KRTX): A Strategic SWOT Insight
Strengths
Innovative CNS-focused Pipeline: Karuna Therapeutics Inc (NASDAQ:KRTX) stands out with its innovative pipeline, particularly its lead product candidate, KarXT, which targets muscarinic receptors in the CNS. This novel approach has shown promise in clinical trials for treating psychosis in schizophrenia and Alzheimer's disease, potentially offering a new standard of care in these areas. The company's focus on CNS disorders, a field with high unmet medical needs, positions it well for future growth.
Story continues
Strong Financial Backing: KRTX has demonstrated its ability to secure capital through follow-on public offerings and an equity distribution agreement. With net proceeds of $436.7 million from its March 2023 offering and a new equity distribution agreement allowing for sales of up to $400.0 million in common stock, KRTX has a solid financial foundation to support its R&D efforts and potential commercialization activities.
Weaknesses
Clinical-stage Status with No Product Revenue: As a clinical-stage company, KRTX has yet to generate product revenue, relying instead on capital markets for funding. This status is a significant weakness as it reflects the inherent risks of drug development, including potential delays or failures in clinical trials, which could impact the company's financial stability and investor confidence.
High R&D Expenditures: The company's commitment to R&D is evidenced by its significant investment in research and development activities, with prepaid R&D expenses totaling $35.7 million. While this underscores KRTX's dedication to innovation, it also highlights the company's high cash burn rate, which could strain financial resources if additional funding is not secured or if product candidates do not progress as planned.
Opportunities
Market Expansion through Strategic Collaborations: KRTX has the opportunity to expand its market reach through strategic collaborations. The company's licensing agreement with Zai Lab to develop and commercialize KarXT in Greater China is an example of leveraging partnerships to access new markets and share development costs, which could significantly enhance its global footprint.
Additional Indications for KarXT: The therapeutic potential of KarXT extends beyond its current clinical trials. KRTX plans to explore KarXT in additional indications, which could broaden its applicability and market opportunity. Success in these endeavors could lead to a diversified portfolio and multiple revenue streams in the future.
Threats
Intense Competition in Neuropsychiatric Drug Market: KRTX faces intense competition from established pharmaceutical companies and emerging biotechs in the neuropsychiatric drug market. Competitors with greater resources and established market presence could challenge KRTX's ability to secure a significant market share, even if KarXT is successfully commercialized.
Regulatory Hurdles: The regulatory landscape for drug approval is complex and challenging. KRTX must navigate this environment to bring KarXT to market, and any setbacks or delays in the regulatory process could adversely affect the company's prospects and financial condition.
In conclusion, Karuna Therapeutics Inc (NASDAQ:KRTX) exhibits a strong position in the CNS-focused therapeutic space with its innovative pipeline and solid financial backing. However, the company's clinical-stage status and reliance on capital markets underscore the risks associated with drug development. Opportunities for market expansion and exploration of additional indications for KarXT present potential growth avenues. Nonetheless, KRTX must navigate the competitive landscape and regulatory challenges to realize its full potential. Investors should weigh these factors carefully when considering KRTX as part of their investment portfolio.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
- Karuna Therapeutics Inc (KRTX) Reports Increased Yearly Net Loss Amid Advancements in Clinical ...
Feb 22, 2024
Net Loss: Karuna Therapeutics Inc (NASDAQ:KRTX) reported a net loss of $113.8 million for Q4 2023 and $433.7 million for the full year. Operating Expenses: Yearly operating expenses rose to $495.4 million, driven by R&D and pre-commercialization activities. Research and Development: R&D expenses increased to $364.1 million for the year, reflecting investment in clinical programs and licensing. Cash Position: The company ended the year with $1.3 billion in cash, cash equivalents, and investments. Pipeline Progress: KarXT's NDA for schizophrenia treatment is under FDA review with a PDUFA date set for September 26, 2024. Proposed Acquisition: The anticipated acquisition by Bristol Myers Squibb is expected to close in the first half of 2024.
Warning! GuruFocus has detected 5 Warning Signs with KRTX.
On February 22, 2024, Karuna Therapeutics Inc (NASDAQ:KRTX) released its 8-K filing, disclosing its financial results for the fourth quarter and full year ended December 31, 2023, and providing updates on its business operations. The clinical-stage biopharmaceutical company, known for its focus on developing novel therapies for neuropsychiatric conditions, highlighted the progress of its lead product candidate, KarXT, an oral modulator of muscarinic receptors.
Financial Performance and Challenges
Karuna Therapeutics Inc (NASDAQ:KRTX) reported a significant increase in its net loss, which amounted to $113.8 million for the fourth quarter and $433.7 million for the full year, compared to $76.2 million and $276.3 million for the same periods in the previous year, respectively. This increase in net loss was primarily due to a surge in operating expenses, which reached $495.4 million for the year, compared to $300.3 million in the prior year. The rise in expenses was attributed to the company's ongoing clinical trials for KarXT, NDA-supporting activities, pre-commercialization efforts, and the costs associated with the pending acquisition by Bristol Myers Squibb.
Story continues
The company's research and development expenses also saw a substantial increase, totaling $364.1 million for the year, driven by the clinical development of KarXT, licensing payments for TRPC4/5 channel candidates, and an increase in employee headcount and stock-based compensation. General and administrative expenses followed suit, rising to $131.3 million for the year, largely due to pre-commercialization activities and the pending acquisition.
Financial Achievements and Importance
Despite the increased losses, Karuna Therapeutics Inc (NASDAQ:KRTX) ended the year with a strong cash position, reporting $1.3 billion in cash, cash equivalents, and available-for-sale investment securities. This financial strength is crucial for the company as it prepares for the potential launch of KarXT for schizophrenia treatment, pending FDA approval, and continues to invest in its pipeline of novel drug candidates for various psychiatric and neurological conditions.
The company's robust cash reserves are particularly important in the biotechnology industry, where significant capital is required to fund extensive research and development activities, clinical trials, and potential commercialization efforts. The financial resources also provide the company with the flexibility to navigate the lengthy and costly process of bringing new therapies to market.
Key Financial Metrics and Commentary
Key financial metrics from the income statement and balance sheet include:
"The Company reported a net loss of $113.8 million for the fourth quarter of 2023, and a net loss of $433.7 million for the year ended 2023, as compared to $76.2 million and $276.3 million for the prior year periods, respectively."
"The Company ended the year 2023 with $1.3 billion in cash, cash equivalents, and available-for-sale investment securities compared to $1.1 billion as of December 31, 2022."
These metrics highlight the company's financial health and its ability to sustain its operations and growth initiatives. The net loss figures reflect the company's stage of development and its focus on investing in its product pipeline, which is a common characteristic of clinical-stage biopharmaceutical companies.
Analysis and Future Outlook
Karuna Therapeutics Inc (NASDAQ:KRTX) is at a pivotal stage with the FDA's review of KarXT for schizophrenia treatment and the proposed acquisition by Bristol Myers Squibb. The company's financial results reflect its strategic investments in research and development, which are essential for advancing its pipeline and achieving its mission to bring transformative medicines to patients with serious mental illnesses.
The anticipated milestones, including the potential approval and launch of KarXT, along with the initiation of new clinical trials, will be critical in shaping the company's future. The proposed acquisition by Bristol Myers Squibb is expected to further support Karuna's growth and enhance its ability to deliver on its promises to stakeholders and patients alike.
For more detailed information on Karuna Therapeutics Inc (NASDAQ:KRTX)'s financial results and business updates, investors and interested parties are encouraged to review the full 8-K filing.
Explore the complete 8-K earnings release (here) from Karuna Therapeutics Inc for further details.
This article first appeared on GuruFocus.
- Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Feb 22, 2024
New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024
Results from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia published in The Lancet
Announced appointments of Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel
Previously announced proposed acquisition of Karuna by Bristol Myers Squibb expected to close in the first half of 2024
$1.3 billion in cash, cash equivalents, and available-for-sale investment securities
BOSTON, February 22, 2024--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
"2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with a potential launch in the second half of this year, and the continued advancement of our late-stage pipeline of KarXT as a potential adjunctive treatment for schizophrenia and in psychosis in Alzheimer’s disease," said Bill Meury, president and chief executive officer of Karuna Therapeutics. "We look forward to continuing the work to bring KarXT and other potentially transformative medicines to patients living with serious mental illnesses, and we believe the pending acquisition of Karuna by Bristol Myers Squibb will accelerate our ability to achieve this mission."
KEY PIPELINE HIGHLIGHTS
Karuna is advancing a pipeline of novel drug candidates for the treatment of various psychiatric and neurological conditions led by KarXT (xanomeline-trospium), an oral, investigational M1/M4-preferring muscarinic agonist.
KarXT
The NDA for KarXT for the treatment of schizophrenia in adults is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of September 26, 2024. KarXT is also being evaluated in Phase 3 clinical trials as a potential adjunctive treatment for schizophrenia and as a potential treatment for psychosis in Alzheimer’s disease.
Story continues
Schizophrenia
The NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by the FDA in the fourth quarter of 2023 and assigned a PDUFA action date of September 26, 2024. Results from the EMERGENT-2 trial published in The Lancet in December 2023. The published manuscript, titled "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial," is available online, and appears in the January 13, 2024 print issue. Announced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023. Results from the trial demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. Presented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023. Poster presentations included new pooled efficacy and safety analyses across the three completed EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials, where:
KarXT demonstrated statistically significant and clinically meaningful improvements in symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 5 compared to placebo (p<0.0001), the primary endpoint in the trials. KarXT demonstrated statistically significant improvements across all secondary efficacy measures, including the PANSS positive subscale score (p<0.0001), PANSS negative subscale score (p<0.0001), PANSS Marder negative factor score (p<0.0001), and CGI-S score (p<0.0001). KarXT was generally well tolerated, with common adverse reactions (>5% and at least twice placebo) being mostly cholinergic in nature, mild to moderate in severity, and transient over time. Further, KarXT was not associated with weight gain, adverse changes in metabolic parameters, or extrapyramidal symptoms. Interim long-term data from the EMERGENT-4 & 5 trials to be presented at upcoming medical congresses in the spring. Adjunctive treatment in schizophrenia
Topline data from the Phase 3 ARISE trial evaluating the efficacy and safety of KarXT in schizophrenia when combined with a background antipsychotic is anticipated in 2025. Psychosis in Alzheimer’s disease
Topline data from the Phase 3 ADEPT-1 and ADEPT-2 trials evaluating KarXT in psychosis in Alzheimer’s disease is anticipated in 2026.
Early-stage and discovery programs
The Karuna pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, as well as pre-clinical muscarinic, TRPC4/5, and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
The Company is on track to initiate a Phase 1b trial of KAR-2618 in major depressive disorder (MDD) in 2024.
BUSINESS UPDATES
Key leadership appointments. In January 2024, the Company appointed Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel. Dr. Miller succeeds Steve Paul, M.D., who continues to serve on the Company’s Board of Directors and was appointed as a member of the Company’s Scientific Advisory Board.
Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb. In December 2023, Karuna and Bristol Myers Squibb announced they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The Boards of Directors of both companies have unanimously approved the transaction. The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval of Karuna stockholders and receipt of required regulatory approvals.
ANTICIPATED UPCOMING MILESTONES
Topline data from the Phase 3 EMERGENT-4 trial (2H 2024) Topline data from the Phase 3 EMERGENT-5 trial (2H 2024) KarXT in schizophrenia PDUFA action date (September 26, 2024) Launch of KarXT in schizophrenia, if approved (2H 2024) Initiation of the Phase 1b trial of KAR-2618 in major depressive disorder (2024) Topline data from the Phase 3 ARISE trial (2025) Topline data from the Phase 3 ADEPT-1 trial (2026) Topline data from the Phase 3 ADEPT-2 trial (2026)
FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
The Company reported a net loss of $113.8 million for the fourth quarter of 2023, and a net loss of $433.7 million for the year ended 2023, as compared to $76.2 million and $276.3 million for the prior year periods, respectively. The increase in net loss for the year was primarily attributable to higher operating expenses of $495.4 million compared to $300.3 million for the prior year period, driven by research and development expenses related to the Company’s ongoing KarXT clinical programs, NDA-supporting activities, pre-commercialization activities, the $15.0 million upfront license payment for Goldfinch Bio’s TRPC4/5 channel candidates, increased employee headcount across the organization, higher stock-based compensation, and expenses associated with the pending acquisition of Karuna by Bristol Myers Squibb.
Research and development expenses were $82.2 million for the fourth quarter of 2023, and $364.1 million for the year ended 2023, as compared to $66.0 million and $224.2 million for the prior year periods, respectively. The increase in research and development expenses for the year was primarily driven by expenses related to the Company’s KarXT clinical programs, NDA-supporting activities, the upfront license payment for Goldfinch Bio’s TRPC4/5 channel candidates, increased employee headcount, and higher stock-based compensation.
General and administrative expenses were $47.4 million for the fourth quarter of 2023, and $131.3 million for the year ended 2023, as compared to $24.3 million and $76.1 million for the prior year periods, respectively. The increase in general and administrative expenses for the year was primarily driven by the Company’s pre-commercialization activities, increased employee headcount, higher stock-based compensation, and expenses associated with the pending acquisition of Karuna by Bristol Myers Squibb.
The Company ended the year 2023 with $1.3 billion in cash, cash equivalents, and available-for-sale investment securities compared to $1.1 billion as of December 31, 2022. The increase was primarily the result of the completion of the Company’s follow-on public offering in March 2023, which resulted in net proceeds of $436.7 million.
About Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the timing of our ongoing and planned clinical trials and regulatory filings, our goals to develop and commercialize our product candidates, our liquidity and capital resources, the proposed acquisition of Karuna by Bristol Myers Squibb, and other statements identified by words such as "could," "expects," "intends," "may," "plans," "potential," "should," "will," "would," or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to obtain necessary funding, our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, the proposed acquisition of Karuna by Bristol Myers Squibb, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent filings with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, 2023 2022 2023 2022 License and other revenue $ — $ 5,278 $ 654 $ 10,637 Operating expenses: Research and development 82,192 66,004 364,101 224,247 General and administrative 47,394 24,310 131,330 76,066 Total operating expenses 129,586 90,314 495,431 300,313 Loss from operations (129,586 ) (85,036 ) (494,777 ) (289,676 ) Other income, net: Interest income 16,285 9,567 61,179 14,178 Sublease income 147 147 588 580 Total other income, net 16,432 9,714 61,767 14,758 Net loss before income taxes (113,154 ) (75,322 ) (433,010 ) (274,918 ) Income tax provision (670 ) (890 ) (670 ) (1,418 ) Net loss attributable to common stockholders $ (113,824 ) $ (76,212 ) $ (433,680 ) $ (276,336 ) Net loss per share, basic and diluted $ (3.01 ) $ (2.22 ) $ (11.73 ) $ (8.74 ) Weighted average common shares outstanding used in computing net loss per share, basic and diluted 37,780,998 34,406,182 36,959,049 31,629,013
Karuna Therapeutics, Inc. Unaudited Consolidated Balance Sheet Data (in thousands) December 31, 2023 December 31, 2022 Cash, cash equivalents and investments $ 1,260,780 $ 1,124,044 Working capital 1,247,184 1,120,823 Total assets 1,336,209 1,163,334 Total stockholders’ equity $ 1,254,235 $ 1,126,238
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222875274/en/
Contacts
Investors:
Alexis Smith
+1 (617) 352-9917
asmith@karunatx.com
Media:
Julie Ciardiello
+1 (917) 647-0159
julie.ciardiello@karunatx.com
- Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Feb 22, 2024 · businesswire.com
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update. “2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with.
